{"Clinical Trial ID": "NCT00645333", "Intervention": ["INTERVENTION 1:", "MK-0752 and Docetaxel", "MK-0752 increased oral doses 1-3 days followed by docetaxel 80 mg/m2 IV on day 8, and pegfilgrastim 6mg SQ day 9. Repeated cycle every 21 days."], "Eligibility": ["Incorporation criteria:", "\u2022 Men or women with metastatic breast cancer (Stage IV) or locally advanced breast cancer (Stage IIIA > 10 cm, or Stages IIIB and IIIC) who have not responded to first-line anthracycline chemotherapy, for which docetaxel is a recommended treatment", "Presence of a measurable or evaluable disease", "Adequate function of the organ", "\u2022 Ability to swallow intact capsules of study medicinal products", "Zubrod Performance Status 0-1 with at least a life expectancy of 3 months", "The time required should be elapsed from prior antineoplastic treatment with acute toxicity resolution.", "- Exclusion criteria:", "\u2022 Concomitant treatment with hormone therapy to treat cancer", "Radiotherapy within 7 days of the first dose", "Central nervous system symptomatic and/or epidural metastases or symptomatic carcinoma or radiotherapy treatment completed in the last 8 weeks", "A serious co-morbid disease that will limit the patient's ability to receive safe cancer treatment", "Pregnant or lactating patients", "- Confounding factors present to provide an erroneous interpretation of the data (i.e., concurrent malignancy)"], "Results": ["Performance measures:", "Dose Limiting Toxicity (DLT)", "The number of DLTs experienced by participants during the first 21 days.", "DLTs were defined as potential, probable or definitive drug-related toxicities observed in the first two cycles (first 42 days) as follows:", "Non-haematological toxicity Grade 3 by version 3.0 of the NCI CTCAE.", "ANC < 1000 for more than 7 days despite the use of pegfilgrastim.", "Number of platelets < 25,000 for more than 7 days, or associated with bleeding, or less than 10,000 at any time.", "Time limit: first 21 days", "Results 1:", "Title of the arm/group: MK-0752 and Docetaxel", "Description of the arm/group: MK-0752 increased doses, oral days 1-3, followed by docetaxel 80 mg/m2 IV on day 8, and pegfilgrastim 6mg SQ day 9. Repeated cycle every 21 days.", "Total number of participants analysed: 30", "Type of measurement: Number", "Unit of measurement: dose limiting toxicity 5"], "Adverse Events": ["Undesirable Events 1:", "Total: 16/30 (53.33 per cent)", "*1/30 (3.33%)", "Abdominal pain *1/30 (3.33%)", "Diarrhoea *2/30 (6.67%)", "Members of edema *1/30 (3.33%)", "*2/30 (6.67%)", "*1/30 (3.33%)", "Immune system disorders *1/30 (3.33%)", "*2/30 (6.67%)", "*1/30 (3.33%)", "Fracture *1/30 (3.33%)"]}